Unicentric mixed variant Castleman disease associated with intrabronchial plasmacytoma

Diagnostic Pathology

Veronika Müller⁴  György Losonczy⁴  György Balázs²  Gergely Varga¹  Ágota Szepesi⁵  Judit Csomor⁵  Attila Csekeő³  Lilla Tamási⁴  Noémi Eszes⁴ 

[1] 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary;Department of Diagnostic Radiology, Heart Center, Semmelweis University, Budapest, Hungary;Koranyi National Institute for Tuberculosis and Pulmonology, Budapest, Hungary;Department of Pulmonology, Semmelweis University, Diósárok u. 1/c, 1125 Budapest, Hungary;1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

关键词: Intrabronchial plasmacytoma;    Extramedullary plasmacytoma;    Mixed variant;    Unicentric;    Castleman disease;   

Others  :  802218
DOI  :  10.1186/1746-1596-9-64

 received in 2014-01-27, accepted in 2014-03-07,  发布年份 2014

【 摘 要 】

Virtual slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2872096831190851. webcite

Castleman disease (CD), described as a heterogeneous lymphoproliferative disorder, can be divided into different subtypes according to clinical appearance (unicentric and multicentric form) and histopathological features (hyaline vascular, plasma cell, mixed type, human herpesvirus 8–associated and multicentric not otherwise specified). Unicentric CD is known to be usually of the hyaline vascular variant, plasma cell and mixed type of this form are quite uncommon. Malignancies are mainly associated with the multicentric form. We report a rare case of unicentric mixed variant CD evolving into intrabronchial, extramedullary plasmacytoma.

Intrabronchial mass with consequential obstruction of the left main bronchus, left lung atelectasis and mediastinal lymphadenomegaly was detected by chest CT in our patient suffering from cough and hemoptysis. Pulmonectomy was performed, histopathological and immunhistochemical analysis of lymph nodes revealed mixed type of CD with interfollicular monotypic plasma cell proliferation. The intrabronchial mass consisted of monotypic plasma cells confirming plasmacytoma. Systemic involvement was not confirmed by further tests.

Although malignancies more often present in multicentric CD that usually belongs to the plasma cell subtype, this case confirms the neoplastic potential of the rarest, unicentric mixed variant of CD.

【 授权许可】

   
2014 Eszes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Slotwiner A, Garwacki CP, Moll S: Castleman’s disease. Am J Hematol 2003, 73:64-65.
• [2]Frizzera G: Castleman’s disease and related disorders. Semin Diagn Pathol 1988, 5:346-364.
• [3]Hakozaki M, Tajino T, Yamada H, Kikuchi S, Hashimoto Y, Konno S: Intramuscular Castleman’s disease of the deltoid: a case report and review of the literature. Skeletal Radiol 2010, 39:715-719.
• [4]Cronin DMP, Warnke RA: Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009, 16(4):822-830.
• [5]Castleman B, Iverson L, Pardo M: Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 1956, 9:822-830.
• [6]Keller AR, Hochholzer L, Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972, 29(3):670-683.
• [7]Hall PA, Donaghy M, Cotter FE, Stansfeld AG, Levison DA: An immunohistological and genotypic study of the plasma cell form of Castleman’s disease. Histopathology 1989, 14:333-346.
• [8]Radaszkiewicz T, Hansmann ML, Lennert K: Monoclonality and polyclonality of plasma cells in Castleman’s disease of the plasma cell variant. Histopathology 1989, 14:11-24.
• [9]Chilosi M, Menestrina F, Lestani M, Bonetti F, Scarpa A, Caligaris-Cappio F, Pizzolo G, Perini A, Fiore-Donati L: Hyaline-vascular type of Castleman’s disease (angiofollicular lymph node hyperplasia) with monotypic plasma cells; an immunohistochemical study with monoclonal antibodies. Histol Histopathol 1987, 2:49-55.
• [10]El Demellawy D, Herath C, Truong F, Nasr A, Alowami S: Localized early mesenteric Castleman’s disease presenting as recurrent intestinal obstruction: a case report. Diagn Pathol 2009, 4:42. BioMed Central Full Text
• [11]Curioni S, D’Amico M, Quartagno R, Martino S, Dell’Antonio G, Cusi D: Castleman’s disease with nephrotic syndrome, amyloidosis and autoimmune manifestations. Nephrol Dial Transplant 2001, 16(7):1475-1478.
• [12]Muskardin TW, Peterson BA, Molitor JA: Castleman disease and associated autoimmune disease. Curr Opin Rheumatol 2012, 24(1):76-83.
• [13]Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF: HIV-associated lymphomas and gamma-herpesviruses. Blood 2009, 5;113(6):1213-1224.
• [14]Wilkinson S, Forrester-Wood CP: Surgical resection of a solitary plasmacytoma originating in a rib of a patient with Castleman’s disease. Ann Thorac Surg 2003, 75:1018-1019.
• [15]Shuaipaj T, Abutalib SA, Chen YH, Gaitonde S, Lindgren V: Intracranial plasmacytoma mimicking meningioma in a patient with Castleman’s disease. Am J Hematol 2009, 84:195.
• [16]Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS: Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol 2009, 144(1):86.
• [17]Nagai K, Sato I, Shimoyama N: Pathohistological and immunohistochemical studies on Castleman’s disease of the lymph node. Virchows Arch A Pathol Anat Histopathol 1986, 409(2):287-297.
• [18]Schlosnagle DC, Chan WC, Hargreaves HK, Nolting SF, Brynes RK: Plasmacytoma arising in giant lymph node hyperplasia. Am J Clin Pathol 1982, 78(4):541-544.
• [19]Lin BT, Weiss LM: Primary plasmacytoma of lymph nodes. Hum Pathol 1997, 28:1083-1090.
• [20]Menke DM, Horny HP, Griesser H, Tiemann M, Katzmann JA, Kaiserling E, Parwaresch R, Kyle RA: Primary lymph node plasmacytomas (plasmacytic lymphomas). Am J Clin Pathol 2001, 115(1):119-126.
• [21]Menke DM, DeWald GW: Lack of cytogenetic abnormalities in Castleman’s disease. South Med J 2001, 94:472-474.
• [22]Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, Meignin V, Oksenhendler E, Boshoff C, Isaacson PG: Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001, 97:2130-2136.
• [23]Hsi ED, Lorsbach RB, Fend F, Dogan A: Plasmablastic lymphoma and related disorders. Am J Clin Pathol 2011, 136(2):183-194.
• [24]Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 1989, 74:1360-1367.
• [25]Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW: Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 1990, 86:592-599.
• [26]Burger R, Wendler J, Antoni K, Helm G, Kalden JR, Gramatzki M: Interleukin-6 production in B-cell neoplasias and Castleman’s disease: evidence for an additional paracrine loop. Ann Hematol 1994, 69:25-31.
• [27]Arlet JB, Hermine O, Darnige L, Ostland V, Westerman M, Badoual C, Pouchot J, Capron L: Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway. Pediatrics 2010, 126(6):e1608-e1612.
• [28]Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G: Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999, 93:4034-4043.
• [29]Sun X, Chang KC, Abruzzo LV, Lai R, Younes A, Jones D: Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman’s disease. Hum Pathol 2003, 34:835-840.
• [30]Zhang L, Lin H, Gao L, Li L, Tian Y, Liu Z, Shi X, Liang Z: Primary central nervous system plasmablastic lymphoma presenting in human immunodeficiency virus-negative but epstein-barr virus-positive patient: a case report. Diagn Pathol 2012, 7:51. BioMed Central Full Text
• [31]Murray PG, Deacon E, Young LS, Barletta JM, Mann RB, Ambinder RF, Rowlands DC, Jones EL, Ramsay AD, Crocker J: Localization of epstein-barr virus in Castleman’s disease by in situ hybridization and immunohistochemistry. Hematol Pathol 1995, 9:17-26.
• [32]Terada T: CD5-positive marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) of the lung. Diagn Pathol 2012, 7:16. BioMed Central Full Text
• [33]Tsukamoto N, Kojima M, Uchiyama T, Takeuchi T, Karasawa M, Murakami H, Sato S: Primary cutaneous CD5+ marginal zone B-cell lymphoma resembling the plasm cell variant of Castleman’s disease. APMIS 2007, 115(12):1426-1431.
• [34]Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF: The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 1999, 85:706-717.